Adaptive Biotechnologies (ADPT) Free Cash Flow (2018 - 2026)

Adaptive Biotechnologies has reported Free Cash Flow for 9 years, with the latest figure at -$9.7 million in Q1 2026.

• Quarterly Free Cash Flow rose 67.4% year-over-year to -$9.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.9 million (up 66.54% YoY) and the FY2025 annual result came in at -$48.9 million, up 49.27% from the prior year.
• Free Cash Flow fell to -$9.7 million in Q1 2026 per ADPT's latest filing, from $1.4 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $1.4 million in Q4 2025 and troughed at -$67.4 million in Q1 2022.
• A 5-year average of -$29.3 million and a median of -$26.3 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow tumbled 46.73% in 2023, then surged 110.33% in 2025.
• Over 5 years, Free Cash Flow stood at -$17.9 million in 2022, then plunged by 46.73% to -$26.3 million in 2023, then surged by 47.79% to -$13.7 million in 2024, then surged by 110.33% to $1.4 million in 2025, then slumped by 783.3% to -$9.7 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$9.7 million, $1.4 million, and -$9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.